Sanofi, who will lead the global diabetes and cardiovascular care business unit in the company's new organisational structure. "The life sciences team at Google can help us improve the patient ...

Sanofi has added another string to its Pompe ... which progressively attacks the heart and skeletal muscles. The drug is a recombinant version of the enzyme alpha-glucosidase, which is deficient ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

medicines for diabetes and cardiovascular diseases; and established prescription products. Receive News & Ratings for Sanofi ...

Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company ...